DISCO’s pioneering surfaceome mapping platform transforms the current approach of target discovery for large molecule R&D. The technology identifies proteins and protein communities across the entire cancer cell surface in a scalable manner, thus addressing the need for target candidates for both mono- and bi-specific antibodies. These insights enable the development of a multitude of cancer-selective therapies, with the potential to boost efficacy and reducing side effects for patients.
Company Details
- Employees
- 32
- Founded
- -
- Address
- Gottfried-Hagen Straße 62, Cologne,north Rhine-Westphalia 51105,germany
- Industry
- Pharmaceutical Manufacturing
- NAICS
-
Pharmaceutical and Medicine ManufacturingMedicinal and Botanical ManufacturingPharmaceutical Preparation ManufacturingIn-Vitro Diagnostic Substance ManufacturingBiological Product (except Diagnostic) Manufacturing
- Website
- http://www.discopharma.de
- Keywords
- T-CURX GmbH.
- HQ
- Cologne, North Rhine-Westphalia
Disco Pharmaceuticals Gmbh Questions
Disco Pharmaceuticals Gmbh's website is http://www.discopharma.de
Disco Pharmaceuticals Gmbh's LinkedIn profile is https://de.linkedin.com/company/disco-pharmaceuticals-gmbh
Disco Pharmaceuticals Gmbh has
32 employees.
View email and phone details for 32
employees at Disco Pharmaceuticals Gmbh.
Disco Pharmaceuticals Gmbh's industry is
Pharmaceutical Manufacturing
Disco Pharmaceuticals Gmbh's top competitors are
Calliditas Therapeutics,
Asceneuron Sa,
Bright Peak Therapeutics,
Bioptimus,
Tigen,
T-Curx Gmbh,
Memo Therapeutics Ag,
Neustark,
Aavantgarde,
Myricx Bio.
Disco Pharmaceuticals Gmbh's categories are Pharmaceutical Manufacturing
Disco Pharmaceuticals Gmbh's founding year is 2022
